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Abstract: BACKGROUND: Occurring frequently after solid organ and hematopoietic stem cell transplan-
tation, cytomegalovirus (CMV) replication remains a relevant cause of mortality and morbidity in affected
patients. Despite these adverse effects, an increased alloreactivity of natural killer (NK) cells after CMV
infection has been assumed, but the underlying physiopathological mechanisms have remained elusive.
METHODS: We used serial analyses of NK cells before and after CMV infection in kidney transplant
recipients as an in vivo model for CMV primary infection to explore the imprint of CMV infection using
every patient as their own control: We analyzed NK cell phenotype and function in 47 CMV seronega-
tive recipients of CMV seropositive kidney grafts, who developed CMV primary infection posttransplant.
Seronegative recipients of seronegative kidney grafts served as controls. RESULTS: We observed a signif-
icant increase of NKG2C expressing NK cells after CMV infection (mean increase, 17.5%; 95% confidence
interval [95% CI], 10.2-24.9, P < 0.001), whereas cluster of differentiation (CD)57 expressing cells de-
creased (mean decrease, 14.1%; 95% CI, 8.0-20.2; P < 0.001). Analysis of killer immunoglobulin-like
receptor (KIR) expression showed an increase of cells expressing KIR2DL1 as their only inhibitory KIR
in patients carrying the cognate ligand HLA-C2 (mean increase, 10.0%; 95% CI, 1.7-18.3; P = 0.018).
In C2-negative individuals, KIR2DL1 expression decreased (mean decrease, 3.9%; 95% CI, 1.6-6.2; P =
0.001). As for activating KIR, there was no conclusive change pattern. Most importantly, we observed
a significantly higher NK cell degranulation and IFN￿ production in response to different target cells
(target K562, CD107a: mean increase, 9.9%; 95% CI, 4.8-15.0; P < 0.001; IFN￿: mean increase, 6.6%;
95% CI, 1.6-11.1; P < 0.001; target MRC-5, CD107a: mean increase, 6.9%; 95% CI, 0.7-13.1; P = 0.03;
IFN￿: mean increase, 4.8%; 95% CI, 1.7-7.8; P = 0.002). CONCLUSIONS: We report evidence for an
increased function of NK cells induced by CMV infection. This increased in vitro functionality was seen
in NKG2C-positive and NKG2C-negative subsets, arguing for an NKG2C independent mechanism of
action.
DOI: https://doi.org/10.1097/TXD.0000000000000605
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-131677
Published Version
 
 
Originally published at:
Tschan-Plessl, Astrid; Stern, Martin; Schmied, Laurent; Retière, Christelle; Hirsch, Hans H; Garzoni,
Christian; van Delden, Christian; Boggian, Katia; Mueller, Nicolas J; Berger, Christoph; Villard, Jean;
Manuel, Oriol; Meylan, Pascal; Terszowski, Grzegorz (2016). Human cytomegalovirus infection enhances
NK cell activity in vitro. Transplantation Direct, 2(7):e89.
DOI: https://doi.org/10.1097/TXD.0000000000000605
2
Human Cytomegalovirus Infection Enhances NK
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Christian van Delden,6 Katia Boggian,7 Nicolas J. Mueller,8 Christoph Berger,9 Jean Villard,10 Oriol Manuel,11
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Background.Occurring frequently after solid organ and hematopoietic stem cell transplantation, cytomegalovirus (CMV) replication
remains a relevant cause of mortality andmorbidity in affected patients. Despite these adverse effects, an increased alloreactivity of nat-
ural killer (NK) cells after CMV infection has been assumed, but the underlying physiopathological mechanisms have remained elusive.
Methods.We used serial analyses of NK cells before and after CMV infection in kidney transplant recipients as an in vivo model for
CMV primary infection to explore the imprint of CMV infection using every patient as their own control: We analyzed NK cell phenotype
and function in 47CMVseronegative recipients of CMVseropositive kidney grafts,whodevelopedCMVprimary infection posttransplant.
Seronegative recipients of seronegative kidney grafts served as controls. Results.We observed a significant increase of NKG2C ex-
pressing NK cells after CMV infection (mean increase, 17.5%; 95% confidence interval [95%CI], 10.2-24.9,P < 0.001), whereas cluster
of differentiation (CD)57 expressing cells decreased (mean decrease, 14.1%; 95% CI, 8.0-20.2; P < 0.001). Analysis of killer
immunoglobulin-like receptor (KIR) expression showed an increase of cells expressing KIR2DL1 as their only inhibitory KIR in patients
carrying the cognate ligandHLA-C2 (mean increase, 10.0%; 95%CI, 1.7-18.3;P= 0.018). In C2-negative individuals, KIR2DL1 expres-
sion decreased (mean decrease, 3.9%; 95% CI, 1.6-6.2; P = 0.001). As for activating KIR, there was no conclusive change pattern.
Most importantly, we observed a significantly higher NK cell degranulation and IFNγproduction in response to different target cells (target
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K562, CD107a: mean increase, 9.9%; 95% CI, 4.8-15.0; P < 0.001; IFNγ: mean increase, 6.6%; 95% CI, 1.6-11.1; P < 0.001; target
MRC-5, CD107a: mean increase, 6.9%; 95% CI, 0.7-13.1; P = 0.03; IFNγ: mean increase, 4.8%; 95% CI, 1.7-7.8; P = 0.002).
Conclusions.We report evidence for an increased function of NK cells induced by CMV infection. This increased in vitro func-
tionality was seen in NKG2C-positive and NKG2C-negative subsets, arguing for an NKG2C independent mechanism of action.
(Transplantation Direct 2016;2: e89; doi: 10.1097/TXD.0000000000000605. Published online 17 June 2016.)
Cytomegalovirus (CMV) remains a common complica-tion after solid organ and allogeneic hematopoietic
stem cell transplantation (HSCT). Cytomegalovirus-induced
multiorgan disease can cause transplantation related morbid-
ity and mortality. Despite these adverse effects, it has been
suggested that CMV triggers increased alloreactivity of natu-
ral killer (NK) cells. This hypothesis origins primarily from
the HSCT setting, with several studies demonstrating a pro-
tective effect on relapse risk for myeloid malignancies in pa-
tients with early CMV reactivation.1-4 The largest study on
this issuewas performed byGreen and colleagues,4 whowere
able to demonstrate an association between CMVantigenemia
and reduced early relapse risk after HSCT but not overall
survival among patients with acute myeloid leukemia.
Even though large efforts have been undertaken to unveil
the role CMV plays in this setting, the pathophysiological
principles underlying this putative protective effect remain
largely unknown.
Human CMV (HCMV) infection has been shown to alter
NK cells by modifying their phenotype, receptor repertoire,
and function.5 Several studies have shown that CMV in-
fection imprints NK cell subpopulations by inducing a
long-lasting expansion of educated NK cells expressing
the NKG2C receptor, involving several other phenotypi-
cal changes including upregulation of self-specific inhibi-
tory killer immunoglobulin like receptors (iKIR) and the
maturation marker cluster of differentiation (CD)57 as
well as loss of the FcεRγ-chain.6-15 These observations
and the fact that NK cells are the first directly cytotoxic
lymphocyte population to recover after HSCT led to the
formulation of an intriguing hypothesis, that a subset of
NKG2CpositivematureNK cells occurring after CMVinfec-
tion mediates anti-tumor activity.
Recently, the protective effect of CMV reactivation on
early relapse risk and early disease-free survival after HSCT
was confirmed in a cohort of allogeneic stem cell recipients
for diverse malignancies after reduced intensity condition-
ing but not myeloablative conditioning.16 Moreover, the
authors found a preferential expansion of donor-derived
CD56dimNKG2C + CD57+ NK cells in reduced intensity
conditioning patients with CMV reactivation and were
able to correlate expansion of these cells to a trend toward
reduced 2-year relapse rate.
Amajor limitation of previous studies assessing the impact
of CMV infection on NK cell phenotype and function is that
individuals with latent chronic infection were compared to
CMV naive subjects. The phenotypic and functional hetero-
geneity of NK cells between individuals make such compari-
sons notoriously complicated. Similarly, studies in stem cell
transplants—undertaken to assess NK cell function during
active CMV replication—faced a comparable issue, as pa-
tients without CMV replication were used as controls.7,17
To circumvent this limitation, we performed NK cell pheno-
type analysis in a cohort of kidney transplant recipients in a
paired fashion (ie, before and after CMV infection) to elimi-
nate interindividual heterogeneity and thus using every pa-
tient as their own control. We chose the kidney transplant
setting as a model for in vivo CMV primary infection, as
there are less confounding factors than in the HSCT setting.
Although the imprint of CMV on NK cells has been con-
firmed in many different settings, the functional significance
of those changes has not yet been clarified. Therefore, we in-
vestigated the response of NK cell subpopulations to a leuke-
mia target and a CMV infected target cell.
Our data indicate a CMV driven increase in NK cell activ-
ity against target cells occurring concomitant to the specific
phenotypic changes. However, this observed alteration in
NK cell function is not limited to the imprinted NKG2C-
positive populations.
MATERIALS AND METHODS
Patient Samples
Frozen peripheral blood mononuclear cells (PBMC) from
kidney transplant recipients were provided by the Swiss
Transplant Cohort Study (STCS), a collaborative approach
of all solid organ transplant centers in Switzerland. Samples
were obtained after written informed consent at defined
timepoints, and the study was performed according to the
regulations of the local ethics committees. Baseline data
(age at transplant, sex, donor and recipient CMV serostatus,
HLA typing, time of CMV infection, etiology of kidney fail-
ure) and data on posttransplant events (immunosuppressive
medication, induction therapy, CMV infection) were pro-
spectively collected by STCS.
For phenotypic analysis and functional assays, PBMCs
were thawed and cultured overnight in Dulbecco modi-
fied eagle medium, supplemented with 10% (v/v) heat-
inactivated fetal-bovine serum, penicillin (100 μ/mL), and
streptomycin (10 μg/mL).
Cell Lines and Viral Strains
As targets for functional assays the fetal human lung fibro-
blast cell lineMRC-5 (provided byA.Helenius, ETHZürich,
Switzerland) and the humanHLA-deficient chronic myeloge-
nous leukemia cell line K562 (provided by ATCC,Manassas,
VA) were used. MRC-5 cells were infected with a wild-type
strain of CMV (provided byH.H.Hirsch, Institute ofMicro-
biology, University Hospital, Basel, Switzerland).
Monoclonal Antibodies and Flow Cytometry
The following monoclonal antibodies were used accord-
ing to the manufacturer's instructions: anti-CD3 Brilliant
Violet 785 (clone OKT3; Biolegend, San Diego, CA); anti-
CD14 Brilliant Violet 785 (clone M5E2; Biolegend); anti-
CD19 Brilliant Violet 785 (clone HIB19; Biolegend);
anti-CD56 Brilliant Violet 605 (clone HCD56, Biolegend);
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anti-CD57 eF450 (clone TB01; eBioscience, San Diego, CA);
anti-NKG2A APC (clone Z199; Beckman Coulter, Brea,
CA), anti-NKG2CAF700 (clone 134591; R&D Systems,Min-
neapolis, MN); anti-KIR2DL1 FITC (clone 143211; R&D Sys-
tems), anti-KIR2DL1/S1 PE-Cy7 (clone EB6B; Beckman
Coulter), biotinylated anti-KIR3DL1 (clone DX9; Biolegend),
anti-KIR3DL1/S1 PE (clone Z27.3.7; Beckman Coulter), anti-
KIR2DL2/L3/S2 PE-Cy5.5 (clone GL183; Beckman Coulter),
anti-KIR2DL3/S2 FITC (clone 1F12, kindly provided by
Etablissement Français du Sang, Nantes, not commercially
available)18; anti-KIR2DL3 PE (clone 180701; R&D Sys-
tems); anti-KIR2DS4 PE-Vio770 (clone JJC11.6; Miltenyi
Biotec, Bergisch-Gladbach), anti-IFNγ FITC (clone B27;
BD Biosciences, Franklin Lakes, NJ); anti-CD107a PE (clone
H4A3; BD Biosciences); 4′,6-diamidin-2-phenylindol and
streptavidin PerCP-Cy5.5 (Biolegend).
Human FcR-blocking reagent (Miltenyi Biotec) improved
staining specificity. Unstained controls were used to adjust
for background fluorescence. Compensation controls were
performed on PBMC. The viability dye 4′,6-diamidin-2-
phenylindol was used to gate out dead cells.
Intracellular staining was performed after cell perme-
abilization using fixation buffer and permeabilization wash
buffer (both Biolegend), according to themanufacturer's pro-
tocol. Samples were acquired with a BD LSR Fortessa 18-
color flow cytometer (BD Bioscience). Results were analyzed
using FlowJo version 10 software (Tree Star, Ashland, OR).
All analyses of NK cell subpopulations were performed on
PBMC. Natural killer cells were defined as the CD3-CD14-
CD19-CD56+ population. Phenotypical analyses of NKG2C,
CD57 and different KIRs after CMVinfectionwere performed
on a mature subset of CD56dimNKG2A− NK cells (see
Figure 1 for gating strategy). Additionally, we analyzed phe-
notypical and functional changes on CD56dimNKG2A-
NKG2C + CD57+ cells, since these cells have been described
to represent a CMV imprinted NK cell subset.
Functional Assays
To investigate virus-induced NK cell activation, wild-type
HCMV infected MRC-5 cells were seeded at 104 cells/well
in flat-bottom 96-well plates. Uninfected MRC-5 cells were
seeded as controls. After 2 days, infection was confirmed by
qualitatively assessing the cytopathic effect using light mi-
croscopy. Peripheral blood mononuclear cells were added at
3  105 cells per well. Coculture with uninfected MRC-5
served as a negative control. After an incubation time of
24 hours, 3  104 infected and uninfected MRC-5 cells, re-
spectively, were added to boost NK cell activation. Brefeldin
A (BD Bioscience) was added after 1 hour. After 6 hours, cells
were harvested, stained, and analyzed by flow cytometry. Pe-
ripheral blood mononuclear cells incubated with uninfected
MRC-5 cells determined the background level of activation.
To investigate leukemia-induced NK cell activation by
missing-self HLA, K562 cells were seeded at 105 cells/well
in round-bottom 96-well plates. Peripheral blood mononu-
clear cells were added at 5  105 per well. Brefeldin A (BD
Bioscience) was added after 1 hour. After 6 hours, cells were
harvested, stained, and analyzed by flow cytometry. Periph-
eral blood mononuclear cells incubated without target cells
estimated background degranulation. All functional assays
were performed with full PBMC.
HLA Typing
SerologicalHLA typing results for HLA-A and -Bwere ob-
tained from STCS.
For typing of HLA-C, genomic DNA of PBMCs was
isolated from 200ul of whole blood using a commer-
cial kit (QIAamp DNA kit QIAGEN). The presence of
HLA-C1 and -C2 public epitopes was assessed using pub-
lished protocols.19,20
Statistical Analysis
Phenotypic parameters as well as degranulation and IFNγ
expression in total NK cells and NK cell subsets were com-
pared between groups by generalized linear model analysis
(IBM SPSS Statistics). All P values presented are 2-sided
and considered significant if less than 0.05.
RESULTS
Patient Characteristics and Sample Size
Forty-seven CMV seronegative patients receiving a CMV
seropositive kidney graft and 25 CMV seronegative patients
receiving a CMV seronegative kidney graft were included in
the study. All 47 patients in the first group (to be further de-
lineated as CMV group) experienced a CMV primary infec-
tion as measured by viral PCR or CMVantigenemia within
6 months posttransplant, whereas none of the 25 patients
in the second group (to be further delineated as control
group) had measurable CMV replication. Cytomegalovirus
replication in the CMV group occurred after a median of
78 days (range, 30-172 days).
Patient pretransplant and treatment characteristics includ-
ing age at transplant, sex, etiology of kidney failure, induc-
tion therapy, and immunosuppressive agents are depicted in
Table 1, patient KIR ligand status is depicted in Table 2.
Patient samples were obtained from all 5 kidney trans-
plant centers in Switzerland (Basel, Bern, Geneva, Lausanne,
St. Gallen, Zurich). Transplantation was performed between
2008 and 2012.
There was no routine monitoring for viral infections other
than CMV.FIGURE 1. Gating strategy.
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Due to low cell numbers in some frozen PBMC samples
after thawing, not all analyses could be performed on
each sample.
Thus, for phenotypical analysis, 42 of 47 samples in the
CMV group, and 22 of 25 samples in the control group were
evaluable, for the K562 assay, 40 samples in the CMV group
and 18 samples in the control group and for the MRC-5 as-
say, 27 samples in the CMVgroup and 15 samples in the con-
trol group were evaluable.
CMV Infection Promotes NKG2C But Not
CD57 Expression
Expansion of NKG2C+ NK cells within the CD56dim
subset after CMV infection is well established.7,21,22 CD57
defines a subset of mature NK cells,23-25 but it is less well
known if there is an expansion of CD57+ NK cells driven
by CMV infection.
To investigate this issue, we assessed NKG2C and CD57
expression before and after HCMV infection.
In line with published data, we observed a significant in-
crease of NKG2C expressing NK cells after CMV primary
infection compared to the control group (mean increase,
17.5%; 95% confidence interval [95% CI], 10.2-24.9;
P < 0.001; Figure 2A). Interestingly, an at least 2-fold in-
crease could be observed in a majority of patients (33 of
42, 79%). We also observed a slight but statistically non-
significant decrease of the NKG2A expressing fraction
(mean decrease, 6.6%; 95% CI, −3.0 to 16.2; P = 0.18,
data not shown).
Of note, there was a relative increase of not only NKG2C
+CD57+ cells (mean increase, 10.5%; 95% CI, 5.8-15.1;
P < 0.001) but also of NKG2C+CD57− cells (mean increase,
7.4%; 95%CI, 4.2-10.5; P < 0.001; Figures 2B-C), speaking
against the hypothesis, that expanded NKG2C+ cells prefer-
entially express CD57. This relative increase of NKG2C
+CD57+ and NKG2C+CD57− NK cell fractions came at
the expense of the CD57+NKG2C− subset (mean decrease,
24.1%; 95% CI, 17.7-30.6; P < 0.001) but not the CD57
−NKG2C− subpopulation (Figures 2E-F).
Surprisingly, total CD57 expression significantly decreased
(mean decrease, 14.1%; 95% CI, 8.0-20.2; P < 0.001;
Figure 2D).
CMV Promotes Expansion of NK Cells Carrying the
Self-Ligand–Specific KIR2DL1
Next, we investigated the impact of CMVon KIR expres-
sion. According to published data, we expected CMV to trig-
ger an expansion of mature NK cells expressing self-specific
inhibitory KIR as well as activating KIR, with a concurrent
decrease of KIR-negative cells.
Intriguingly, we found a significant increase of cells ex-
pressing 2DL1 as the only inhibitory KIR (negative for
2DL2, 2DL3, 3DL1) in the presence of the cognate ligand
HLA-C2 after CMV infection (C2/C2 or C1/C2: mean in-
crease, 10.0%; 95% CI, 1.7-18.3; P = 0.018; Figure 3B). In
contrast, in the absence of the ligand, there was a significant
decrease of 2DL1 single positive cells (C1/C1: mean decrease,
TABLE 1.
Patient baseline and treatment characteristics
Test group Control group
CMV infection No CMV infection
n = 47 n = 25
Pretransplant characteristics
Median age at transplantation, range 53.5 9-71 58.3 30-70
No. females, % 15 31.9 6 24
Median number of days until CMV
infection, range
78 31-172 n.a.
Center of transplantation (number, %)
Basel 18 38.3 8 32
Bern 2 4.3 3 12
Geneva 3 6.4 1 4
Lausanne 5 10.6 2 8
St. Gallen 0 0 2 8
Zurich 19 40.4 9 36
Etiology (number, %)
Cause unknown 2 4.3 1 4
Diabetic nephropathy 9 19.1 4 16
Glomerulonephritis/Vasculitis 9 19.1 6 24
Hypertensive/renovascular nephrosclerosis 6 12.8 4 16
Interstitial nephritis, not hereditary 1 2.1 1 4
Obstructive nephropathy/Reflux/Pyelonephritis 0 0 1 4
Other causes 6 12.8 4 16
Polycystic kidney disease 8 17 4 16
Other hereditary kidney disease 3 6.4 0 0
Previous allograft failure 2 4.3 0 0
Immunosupressive agents (number, %)
Cyclosporine 15 31.9 12 48
Tacrolimus 38 80.9 20 80
Glucocorticoid 47 100 25 100
MMF 40 85.1 18 72
EC-MPA 9 19.1 9 36
Azathioprine 2 4.3 0 0
Everolimus 2 4.3 0 0
Sirolimus 2 4.3 0 0
Induction therapy (number, %)
Basiliximab 27 57.4 18 72
Rituximab 0 0 1 4
Anti-thymocyte globulin 11 23.4 2 8
IVIG 4 8.5 0 0
CMV prophylaxis (number, %)
Valgancyclovir 42 89.4 0 0
TABLE 2.
Patient HLA typing for C1/C2, Bw4/Bw6
Test group Control group
CMV infection No CMV infection
n = 47 n = 25
HLA status (n, %)
C1/C1 18 38 7 28
C1/C2 14 30 11 44
C2/C2 5 11 3 12
Missing 10 21 4 16
Total 47 100 25 100
Bw4/Bw4 1 2 1 4
Bw4/Bw6 20 43 9 36
Bw6/Bw6 14 30 10 40
Missing 12 26 5 20
Total 47 100 25 100
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3.9%; 95%CI, 1.6-6.2; P = 0.001; Figure 3C).When looking
at overall 2DL1 expression on NK cells, results were similar
(C2/C2 or C1/C2: mean increase, 9.8%; 95% CI, −1.6 to
21.2; P = 0.093; C1/C1: mean decrease, 12.1%; 95% CI,
7.7-16.6; P < 0.001).
When looking at 2DL1 single positivity on a CMV-
imprinted subset of NKG2C+CD57+ cells, results were also
similar with a significant increase in 2DL1 expression in the
presence of the cognate ligand (mean increase, 15.9%; 95%
CI, 3.4-28.3; P = 0.013).
KIR2DL2 expressing cells increased after CMV infection
compared to the control population (mean increase, 6.4%;
95% CI, 0.6-12.3; P = 0.03; Figure 1, SDC, http://links.
lww.com/TXD/A27). KIR2DL2 is known to be licensed
by HLA-C1 as well as HLA-C2. Compatible with this
characteristic, we did not find a difference in 2DL2 expres-
sion according to HLA status.
We observed no significant change in 2DL3 expressing
cells after CMV infection compared with the control group
(mean increase, 1.3%; 95% CI, −4.6 to 7.2, P = ns; Figure. 1,
SDC, http://links.lww.com/TXD/A27), independent of the
presence or absence of the cognate ligand HLA-C1. Sample
size with HLA-C2/C2 status might have been too low to de-
tect a significant difference to HLA-C1 positive individuals
(compare Table 2). Again, we looked at 2DL2 and 2DL3 ex-
pressions on the CMV-imprinted population of NKG2C
+CD57+ cells and found similar results to the overall NK
cell population.
KIR3DL1 expression decreased uponCMVinfection com-
pared to the control group—this was true independently of
FIGURE 2. Changes in expression of different surface molecules. Full lines depict CMV group (n = 42), dotted lines depict control group
(n = 22). Numbers are percent of all CD56dim NKG2A− NK cells. A, NKG2C expressing NK cells increase significantly after CMV infection.
B, NKG2C and CD57 coexpressing cells increase in the CMV group, the same is true for NKG2C+CD57− cells (C). D, Decrease in CD57 ex-
pressing cells after CMV infection. E, The increase of NKG2C+ cells is going at the expense of the CD57+NKG2C− subpopulation, which de-
creases after CMV infection. F, A significant difference between control group and CMV group in the NKG2C−CD57− fraction is observed.
Since this can already be observed before CMV infection, this difference cannot be attributed to CMV infection.
FIGURE 3. Changes in surface expression of 2DL1. Full lines depict CMV group (n = 42), dotted lines depict control group (n = 22). Numbers
are percent of all CD56dimNKG2A−NK cells. A, Overall, cells expressing KIR2DL1 as the only inhibitory KIR do not change after CMV infection
compared to the control group. B, In the presence of the cognate ligand HLA C2, there is a significant increase in 2DL1 expressing cells,
whereas in absence of the cognate ligand, 2DL1 expressing cells decrease (C). D-F, Pattern of change in 2DL1 expression in single patients.
D, CMV group, HLA-C2 positive samples (n = 16). E, CMV group, HLA-C2 negative samples (n = 17). F, Control group (n = 22).
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the presence of the cognate ligandHLA-Bw4 (mean decrease,
8.1%; 95% CI, 4.3-11.9; P < 0.001).
Results were similar when looking at 3DL1 single positive
cells (negative for 2DL1, 2DL2, 2DL3: mean decrease, 3.1%;
95% CI, 1.7-4.7; P < 0.001; Figure 1, SDC, http://links.lww.
com/TXD/A27, Bw4 pos: mean decrease, 2.7%; 95% CI,
−0.2 to 5.6; P = 0.069; Bw4neg: mean decrease, 4.3%;
95% CI, 2.0-6.6; P < 0.001) and when investigating the
NKG2C+CD57+ population (mean decrease, 5.2%; 95%
CI, 1.0-9.3; P = 0.016; Bw4pos: mean decrease, 7.7%;
95% CI, 0.6-14.7; P = 0.033; Bw4neg: mean decrease,
4.5%; 95% CI, −1.5 to 10.4; P = 0.14).
No Expansion of aKIR+ NK Cells After CMV Infection
Is Observed
Previous studies found an inverse correlation between
the number of activating KIR genes in the donor and
the CMV replication risk after hematopoietic stem cell
transplant.26-28 The same effect has been shown in kidney
transplant recipients.29–31
The question has also been raised, weather CMV replica-
tion influences expression of activating KIR posttransplant.
One study demonstrated an elevated expression of aKIR (ie,
KIR2DS2 and KIR2DS4) after HSCT compared with donor
expression before HSCT, above all in CMV viremic com-
pared with CMV nonviremic HSCT recipients.32
In contrast to these observations, we did not find an increase
in aKIR expression after CMV infection in our study setting.
We found a small statistically nonsignificant decrease of
2DS1 expressing cells upon CMV infection (mean decrease
after CMV infection compared with control group, 1.1%;
95% CI, −3.3 to 5.4; P = 0.63; Figure 4A). Interestingly, this
decreasewasmore pronounced in the presence of the cognate
ligand HLA-C2, leading to a significant difference between
groups (C2/C2 or C1/C2: mean decrease, 5.6%; 95% CI,
2.6-8.7; P < 0.001; C1/C1: mean decrease, 0.2%; 95% CI,
−9.0 to 9.3; P = 0.97, data not shown).
No significant change in the expression of 3DS1 and 2DS2
on CMV infection could be observed (Figures 4B-C).
As for KIR2DS4, we found a marked decrease in 2DS4 ex-
pressing cells after CMVinfection compared with the control
group (mean decrease, 16.3%; 95% CI, 5.1-27.4; P = 0.004,
Figure 4D).
When looking at a CMVimprinted, NKG2C+CD57+ sub-
set, results were comparable to the overall population, with
no significant change for 2DS2 and 3DS1, but a more pro-
nounced decrease of 2DS1 expressing cells in the presence
of the ligand (mean decrease, 16.4%; 95% CI, 6.3-26.4;
P = 0.001) and of 2DS4-expressing cells (mean decrease,
13.6%; 95% CI, 2.2-25.1; P = 0.019).
CMV Leads to Increased In Vitro Effector Function
Against Tumor Targets
To address changes in NK cell function after CMVinfection,
we performed coculture experiments with 2 different targets.
First, we investigated whether CMV infection leads to an
increased NK cell function in vitro on stimulation with
HLA-negative tumor cells.We observed a significantly higher
NK cell degranulation (CD107a surface expression: mean
increase, 9.9%; 95% CI, 4.8-15.0; P < 0.001) and IFNγ
production (mean increase, 6.6%; 95% CI, 1.6-11.1;
P < 0.001) in response to K562 after CMV infection com-
pared with the control group. No significant differences
were seen between NKG2C-positive and NKG2C-negative
subsets (Figures 5 and 6).
CMV Leads to Increased In Vitro Effector Function
Against Virus-Infected Target
On coculture with the CMV-infected target cell lineMRC-5,
we also observed an increased degranulation (mean increase
of CD107a surface expression, 6.9%; 95% CI, 0.7-13.1;
P = 0.03) and IFNγ production (mean increase, 4.8%;
95% CI, 1.7-7.8; P = 0.002), but the changes were less dis-
tinct than upon coculture with K562 cells (Figures 5 and 6).
Because induction therapy was different between groups
with most patients receiving either basiliximab (57% in the
CMV group, 72% in the control group) or anti-thymocyte
globulin (23% in the CMV group, 8% in the control group),
we analyzedNKcell phenotype and activity according to induc-
tion therapy regimen, but no difference could be detected (data
not shown). The immunosuppressive regimen was identical for
a far majority of patients included, with 92% in the CMV
group and 100% in the control group receiving a combination
of glucocorticoids, a calcineurin inhibitor, and mycophenolate.
DISCUSSION
Using serial analyses of kidney transplant recipients as a
model for primary in vivo CMV infection, we observed rel-
evant phenotypical and functional changes in the NK cell
compartment. In line with previous results and with the
prevalent understanding of the CMV driven imprinting
process,6-9,11,21,22 we found an increase in NKG2C+ NK
cells. The functional properties of these NK cells in terms
of antiviral and antitumor immunity have, however, remained
elusive. In the hematopoietic stem cell transplant setting,
Foley and colleagues were able to demonstrate a robust IFNγ
production of NKG2C + KIR+ NK cells during CMV infec-
tion, but no increase in degranulation upon stimulation with
K562 cells.
FIGURE 4. Changes in surface expression of different activating
KIR. Full lines depict CMV group (n = 42), dotted lines depict control
group (n = 22). A-C, No significant changes in subpopulations ex-
pressing KIR2DS1, 2DS2 or 3DS1 respectively. D, The subpopula-
tion expressing 2DS4 decreases significantly after CMV infection.
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In the present study, we were now able to demonstrate an
enhanced degranulation as well as IFNγ production of NK
cells induced by CMV infection compared to the CMV naïve
situation, above all when using aHLA-negative leukemia tar-
get cell, but also—albeit to a lesser degree—when using a
CMV-infected target.
Intriguingly, and in contrast to previously published data,
these changes could be seen in the overall CD56dimNKG2A−
NKcell population, and,when looking at subpopulations de-
fined by NKG2C, they were not restricted to NKG2C+
subsets but could also be observed in NKG2C−NK cells. To-
gether with the fact that the tumor target cell line K562 does
not express the NKG2C ligand HLA-E, this argues for an
NKG2C independent mechanism of action.
Upregulation of NKG2C on NK cells is only one of many
different CMV-driven changes on the NK cell compartment,
but does not seem to be causative for the increased activity
we observe in our study setting. Other groups were already
able to conclusively demonstrate the occurrence of CMV-
induced changes on NK cell repertoire in the absence of
NKG2C expression.33,34
Finally, we cannot rule out that other immune players such
as T cells or monocytes interacting with NK cells might en-
hance these observed functional changes, to augment func-
tional capacity of NK cells, because we performed functional
analyses on PBMC and not purified NK cells.
Rölle and colleagues35 were able to demonstrate in vitro
that the expansion of NKG2C+ NK cells in HCMV relies
on crosstalk of NK cells with monocytes, involving IL-12
and being dependent on the interaction with HLA-E on in-
fected cells. In that study, no data on the functional capacity
of NK cell subsets was given, so it can only be speculated that
analogous mechanisms, involving crosstalk between NK
cells and monocytes and dendritic cells might not only trig-
ger phenotypical changes but could also play a role to exert
increased functional capacity of NK cells. A recently pub-
lished study by Wu and colleagues36 demonstrated that
the CMV-induced enhanced antiviral activity of NK cells
is dependent on IL-2 secreted by virus-specific CD4+ T cells,
FIGURE 5. Changes in degranulation (CD107a surface expression) and IFNγ release upon coculture with different target cells. Analyses are
performed on CD56dimNKG2A− NK cells. Full lines depict CMV group (n = 40/27 for K562/MRC-5, respectively), dotted lines depict control
group (n = 18/15 for K562/MRC-5 respectively). A and C, Increased degranulation (A) and IFNγ release (C) on coculture with the tumor target
cell line K562 after CMV infection compared with the control group. B andD, Increased degranulation (B) and IFNγ release (D) on coculture with
the CMV-infected fibroblast cell line MRC-5 after CMV infection. Black lines show netto effect (activation after coculture with uninfected MRC-5
cells has been subtracted). Grey lines show NK cell activation after coculture with uninfected MRC-5 cells. E and F) No difference after CMV
infection between single NK cell subpopulations in degranulation (E) and IFNγ release (F) upon coculture with the tumor target cell line K562;
increased function can be observed in all subpopulations (exception: no increase in IFNγ release in the CD57+G2C− subset after CMV infection).
FIGURE 6. Example of a representative patient (patient 14) with in-
creasing in vitro degranulation and IFNγ release after CMV infection.
Numbers are percentages of all CD56dim NKG2A− NK cells.
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stressing on the importance of the adaptive immune system
onNK cell-mediated immunity. Consistent with our findings,
the authors provided some evidence that this increased NK
cell activity was not mediated by NKG2C+ cells.
In line with previously published findings from our group,37
we observed an expansion of NK cells expressing the self-
specific inhibitory KIR2DL1 on CMV infection and now
could also demonstrate a decrease of 2DL1 expressing cells
in absence of the ligand. The same observation could not be
made for the other inhibitory KIR with known ligands
KIR2DL2, 2DL3, and 3DL1, the latter was even decreasing
after CMV infection independently of presence or absence
of the cognate ligand. Since 2DL2 is known to bind HLA-
C1 and -C2, this might explain why we did not observe a
change according to ligand status. Moreover, the study in-
cluded only few HLA-C2-homozygous controls, what might
have precluded the detection of significant findings for 2DL3,
since the C1-negative control group was too small.
Lopez-Vergès and colleagues9 described a series of solid or-
gan transplant recipients with CMV replication, displaying
an increased frequency of CD57+ NK cells within both
NKG2C+ andNKG2C− subsets, withNKG2C+NK cells be-
ing predominantly CD57− just after the detection of viremia,
and over time increasing the amount of NKG2C on the cell
surface and acquiring CD57 expression. In our study setting,
we detected a relative increase of not only NKG2C+CD57+
cells but also of NKG2C+CD57− cells, speaking against the
hypothesis of expanded NKG2C+ cells preferentially ex-
pressing CD57. Moreover, total CD57+ cells were decreas-
ing. Because we did not dissect the evolution of NKG2C+/
bright cells in the short course of acute infection, results are
not directly comparable.
Similar to our findings of a decrease of 3DL1 expressing
cells in the overall and NKG2C+ NK cell population, the au-
thors stated a preferential decrease of 3DL1 on CD57
+NKG2C+ cells in HLA-Bw4–positive donors and also in a
minority of Bw4 negative donors. An explanation for the
somewhat diverging results might be that changes in 3DL1
expression precede increase in NKG2C (and possibly CD57)
expression. This theory might be reinforced by findings of
De Rham and colleagues38 who also studied kidney transplan-
tation recipients with CMV replication and found an increase
in 3DL1-expressing cells right at the acute phase of the infec-
tion with a rapid fall afterward, also providing some in vitro
evidence that these cells might play a role in CMV control.
It has to be pointed out, that antibody-mediated re-
sponse of NK cells after CMV infection was not examined
in our study setting. Costa-Garcia and colleagues39 re-
cently reported a significant antibody-mediated increase
in degranulation and cytokine production of NK cells
against CMV-infected fibroblast, particularly but not only
in NKG2C-positive cells. Even though we cannot comment
on antibody-dependent cellular cytotoxicity, we provide
evidence for increased direct, antibody-independent cellu-
lar cytotoxicity of NK cells.
In our setting, the number of patients exhibiting an at
least 2-fold expansion of NKG2C-positive NK cells was
substantial (33 of 42 patients, 79%) and was persisting
1 year after transplantation. When comparing CMV sero-
positive to CMV seronegative healthy donors, an expanded
NKG2C-positive NK cell population can be found in a much
lower percentage, arguing for the fact that this expanded NK
cell subset does persist throughout life in many individuals,
but is lost in other individuals, probably depending on the
time lag from CMV primary infection/reactivation.
The fact that NKG2C expressing cells increased by a mean
of 17.5% after CMV infection, NKG2A expressing cells de-
creased by only 6.6%, and there was no increase in double
positive cells argues for a CMV driven emergence of
NKG2C+ cells from the NKG2A−NKG2C–negative subset.
It finally has to be mentioned, that patients in the CMV
group underwent prophylactic therapy with valganciclovir
as well as ganciclovir treatment for CMV disease, while pa-
tients in the control group received none of these. These med-
ications might have had an impact on NK cells. Ganciclovir
has been shown to inhibit proliferation of lymphocytes in
vitro by impairing DNA synthesis,40–42 an issue which has
not been studied specifically for NK cells. Nevertheless, an
antiproliferative effect can be assumed for NK cells just as
for other lymphocyte types but should not be responsible
for the specific changes observed in our study.
To summarize, we are able to demonstrate an increased
function of NK cells induced by CMV infection, above all
but not only against tumor cells and not restricted to cells ex-
pressing the activating receptor NKG2C.
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